-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 FDXtkmbOHiMKJK9dHqfJUI2IP0EpkWCYgg1s2e9Kupqz0SQTQQ74TIdBMl0ou9WA
 ILnbAiVCL11cCuh7Go5Ncg==

<SEC-DOCUMENT>0000950123-09-050643.txt : 20091015
<SEC-HEADER>0000950123-09-050643.hdr.sgml : 20091015
<ACCEPTANCE-DATETIME>20091015161056
ACCESSION NUMBER:		0000950123-09-050643
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20091015
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091015
DATE AS OF CHANGE:		20091015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		091121575

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c91140e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): October 15, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>Lifevantage Corporation<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Colorado</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-30489</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>90-0224471</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>11545 W. Bernardo Court, Suite 301, San<BR>Diego, California<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>92127</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(858) 312-8000</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>&nbsp;</B>


<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.</B>


<P align="left" style="font-size: 10pt">On October&nbsp;15, 2009, we issued a press release reporting our preliminary unaudited financial results for the quarter
ended September&nbsp;30,&nbsp;2009. A copy of the press release is furnished as Exhibit&nbsp;99.1 to this report.


<P align="left" style="font-size: 10pt">The information contained in this Item&nbsp;2.02 and in the accompanying exhibit shall not be deemed filed for purposes of
Section&nbsp;18 of the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or incorporated by reference in
any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.


<P align="left" style="font-size: 10pt">&nbsp;<B>Item&nbsp;9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 10pt; text-indent: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

&nbsp;
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued on October&nbsp;15, 2009 reporting financial results
for the quarter ended September&nbsp;30, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt"><B>&nbsp;</B>


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.


<P align="left" style="font-size: 10pt">Date: October&nbsp;15, 2009



<P align="left" style="margin-left:45%; font-size: 10pt">LIFEVANTAGE CORPORATION



<P align="left" style="margin-left:45%; font-size: 10pt">By: <U>/s/ Carrie E. Carlander&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
<B>Carrie E. Carlander</B><BR><B>
Chief Financial Officer, Secretary &#038; Treasurer</B><BR>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>&nbsp;Exhibit&nbsp;Index</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release issued on October&nbsp;15, 2009 reporting financial results
for the quarter ended September&nbsp;30, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c91140exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">


<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99.1</B>


<DIV align="center"><IMG src="c91140p91140_01.jpg" alt="(LOGO)"></DIV>

<P align="center" style="font-size: 10pt"><B>LIFEVANTAGE ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUE</B>



<P align="center" style="font-size: 10pt"><B>Company Anticipates Second Consecutive Quarter of Double Digit Percentage Increases in Net Revenue</B>



<P align="justify" style="font-size: 10pt"><B>San Diego</B>, <B>CA, October&nbsp;15, 2009</B>, <U>LifeVantage Corporation (OTCBB: LFVN),</U> the maker of Protandim&#174; and
TrueScience&#153; Anti-Aging Cream, science-based solutions to oxidative stress, announced preliminary unaudited net revenue
for the first fiscal quarter of 2010. The Company anticipates net revenue of approximately $1.9&nbsp;million for the three
month period ended September&nbsp;30, 2009, compared to net revenue of $1.6&nbsp;million for the three month period ended June
30, 2009. This continued growth in revenue demonstrates the success of the Company&#146;s on-going expansion into the
network marketing distribution model.


<P align="justify" style="font-size: 10pt">Total operating expenses in the first fiscal quarter of 2010 decreased by approximately 25% from total operating
expenses of $6.1&nbsp;million in the fourth fiscal quarter of 2009. This decline is primarily attributable to reductions of
approximately 80% in total legal expenses. In the first fiscal quarter of 2010, legal expenses decreased by
approximately $1&nbsp;million and other operating expenses decreased by approximately $0.5&nbsp;million. These decreases are
directly attributable to the Company&#146;s efforts in expense reductions and greatly reduced activity in litigation in
which the Company has been a party.


<P align="justify" style="font-size: 10pt">&#147;We are pleased to announce that the Company anticipates its second consecutive quarter of double digit percentage
increases in net revenue,&#148; stated Carrie E. Carlander, Chief Financial Officer of LifeVantage, &#147;especially since both
quarters of revenue increases occurred during a traditionally slower time of year for MLM companies. Moving forward, as
we continue to grow and expand our network marketing business model and make progress on the scientific front, we will
continue to look for ways to decrease expenditures as appropriate as we move towards profitability.&#148;


<P align="justify" style="font-size: 10pt">The Company will hold a conference call today at 1:30pm Pacific time (4:30pm Eastern time) during which it will provide
an update on its business and discuss fourth quarter and fiscal year 2009 financial and operating results as well as
preliminary unaudited financial results for the first fiscal quarter of 2010. David W. Brown, President &#038; Chief
Executive Officer, is scheduled to lead the call and will be joined by Carrie E. Carlander, Chief Financial Officer.


<P align="justify" style="font-size: 10pt">The conference call may be accessed by dialing (888)&nbsp;857-6930 for domestic callers and entering the pass code 5862542.
The webcast will be available live via the Internet by accessing the Investors section of LifeVantage&#146;s website at
<U>http://www.lifevantage.com/investor-profile.aspx</U>. Replays of the webcast will be available on LifeVantage&#146;s
website for 30&nbsp;days and a phone replay will be available through October&nbsp;20<SUP style="font-size: 85%; vertical-align: text-top">th</sup>, 2009 by dialing (888)
203-1112 and entering the pass code 5862542.


<P align="justify" style="font-size: 10pt"><B>About LifeVantage Corporation</B>
<BR>
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, nutraceutical company dedicated to helping
people reach their health and wellness goals. Founded in 2003 and based in San Diego, CA, LifeVantage develops
products, including Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup>, that deliver significant health benefits to consumers. For more information,
visit <U>www.LifeVantage.com</U>.



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center"><IMG src="c91140p91140_01.jpg" alt="(LOGO)"></DIV>

<P align="justify" style="font-size: 10pt"><B>Forward Looking Statements</B>
<BR>
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current
prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148; &#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148;
&#147;anticipates&#148; and variations thereof, identify forward-looking statements, but their absence does not mean that a
statement is not forward-looking. Such forward-looking statements are not guarantees of performance and the Company&#146;s
actual results could differ materially from those contained in such statements. These forward-looking statements are
based on the Company&#146;s current expectations and beliefs concerning future events affecting the Company and involve
known and unknown risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be materially
different from those anticipated and discussed herein. These risks and uncertainties include, among others, the
potential failure or unintended negative consequences of the implementation of our network marketing sales channel; our
ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the
potential for third party and governmental actions involving our network marketing sales channel; the potential for
product liability claims against the Company; the risk that&nbsp;government regulators and regulations could adversely
affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable
publicity could materially hurt our business; and the Company&#146;s ability to protect our intellectual property rights and
the value of our product. These and other risk factors are discussed in greater detail in the Company&#146;s Annual Report on
Form 10-K and Quarterly Report on Form 10-Q under the caption &#147;Risk Factors&#148;, and in other documents filed by the
Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based
on information currently available to the Company on the date hereof, and the Company undertakes no obligation to
revise or update these forward-looking statements to reflect events or circumstances after the date of this document,
except as required by law.


<P align="justify" style="font-size: 10pt">*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to
diagnose, treat, cure or prevent any disease.


<P align="center" style="font-size: 10pt"><B>###</B>



<P align="justify" style="font-size: 10pt"><B>Investor Relations Contact:</B>
<BR>
Ioana C. Hone
<BR>
(858)&nbsp;312-8000 Ext. 4


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c91140p91140_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c91140p91140_01.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$(`\0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@!*2:Z=`M86F&VFP4KI6`3('>ANWD
M"\A:8!275+H`F13L*ZV#(H'86@`I-I+R`*+K0!*=A70M`PZ4;>0"<4+R#;R%
MH`3(_*AZ>0+RZ"T+R`*`"@`I:;`)Q3VT!>0<"DFM4N@6%HNDK]`\NP4)KH`4
MP"@`H`*`"@!#T/T/\J/R$[V=M[:$&2.Y%"E35TM+`XSLK"Y/J:F.B:2]`M[R
MN&3ZD?TJVXI[:H?+*SZ)['B_[07Q8B^"?P?\;_$EX%N;GP]I3-IEHYVI<ZO=
M.MIIL4A_YY"ZFC=P/X%:NK+</]=Q4*+5HWU\DO\`/;RW.+,:[P6&E4A\25E_
MF?@#X8^-/[?_`,=;_P`0^)OAOXP^).HPZ7(9[ZQ\*W4>G^'].>4&6&RAM'`B
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M>K_'_P`7_`P:.\$GA7P)IOC0ZWYIVW2ZCJ<&G"R$?\+*9@^[T%=U7"J&&IUT
M[NIIR]%HW^APPQ/-B9T.7V?+U74]UR?4_P`JXY>XK1C_`,`[$D_M6L&3ZFIO
M+=+Y`W;38,GU-4I*U^O;L%GS15K*VX9;U/\`A1&*=Y;/L%VI6M[JZAD^N*2O
M"'O?%T'I=\NB[!D^III**5TE<3[I\JB&3ZG^5&FL6K+IZ!:R4EL&2.AIQY->
M7H-J2MI:X9/J?;M4JV_-I+1(?1Q2LTAR$YZ]OZBJ<4EH1%NVI+2*"@`H`\_^
M+/BV[\`?"OXE^.["WAN[_P`%?#_QEXMLK6XR(+F[\.>'-2UBVMYRI!$,DUFB
M-@@[6.*Z<'16(Q>%H/:O6I4WZ3G&/ZF&*JNAA<366]&E4FO^W(.7Z'Q1^Q!^
MV#XN_:@U;X@:=XG\.Z3H4?A'3=#O+1]->0O</JEU>P2B;S&;`5;92,>IKU,Y
MRJEETZ<8?:;_`"N>5E&:3QJJ7TY%?:W5+]3]#_TKQ&XQLDCW/L\W8^!_VX_V
ML/%?[+EA\/[KPQH&E:XWBR[UJWO!J;2J(!IEK%/$T(B=269Y#G/I7NY+EM+'
MRJJI?W-DG;I?HT>'G.85<%[)4[)2[^J7ZGE_[6OCW4/B=_P3[T_Q_J=K!8:A
MXMMO#&JWMI:EC:V\LVI.K1IDY,>V,=2>:WRFA&CG%2@M(T[I>ET<V:8AU<II
MUNL_S/S;_9E_;C\4_LS^`]1\&:!X!T_Q%!>ZS-K4VH3FZ64S3QK&('-M@%%1
M!@G)&<=Z^CS?*,-BJD:DZKA*$79)JW<\'*<SKX2G.$()QE)=-K+_`()^SGQ>
M_;+\'?!?X.>"O'_B>T^U^+_'GAK3=7T+P992;9I;J^T^"\F:=WRUOI]O).JM
M(PR<;1R<CY#"Y/4Q6*G15XT:;LY?Y?YGU.(S>&%PL*K2]K-74>Q^:$G_``5`
M_:&>Y/B"#X?Z3'X8$H98AIM^UF(0W^K.HXVYQP6S7TG^KF7I*E[1*I;^97_,
M^?7$&.3=3D]R_9VM]UC]1_V4_P!K7P=^TYX=NI;&W/A_QKH:(/$'AF=PYC60
M8CO]/ER/M%E(PP3C*'@]:^9S+**F65==:4MGZGTF79E',*3Y7RU(K5;'6_"3
MX\?\+#^(WQ:^%^L:"?#GBGX7ZK:QBV:<2KK6@:@"MGK4'`*PM,/+(YP>]<V*
MP,</2HUH.\:JO\[7_(VPV-=:K5H27*Z;]-+V_-GT4.G&?Y'TY],?3TKSU=I/
M\#TK*+L?.<OQZ$_[05Y\$-%\/R:I#X=\$R^,O&?B&&7>FAHY*Z=IBVZC,EW<
MN-JKG.37H?4W]6IUW[JJ2Y8WT6KLF_S?9'G_`%Q*O5I1_P"7<;M+RU9X7<_M
M7_&[QM?WL?P2_9L\4ZYH-G>7%G'XF\8/_8-G?/:NT4KPVTF)(EWHP`);/!SS
M78L!@\/"+Q6(Y7+90:_(XGC<75DXX6EMOS(U_`G[7^N67CC2/AO^T'\+M:^#
MWB#Q--]D\+:W=$77A?6[XG"V"7Z_+!,_)0LWS$!<<YI5,K56C*O@I*I3C>Z;
M7-IV6_<NEF$J554<5%TYO:RLO\CV/XR_'[2_@UXN^%>A:U9P#1_B#J^JV.I:
M[<7*V]OH-EI6D76JS:A(6&)5\NV*[1@DNN.37-A<NEBZ-?V3M.C;3;<Z,3CE
MA:M#VEE"K?;=6/`V_:9_:(^(;W.M_`7X!'6?`,4LRZ;XD\:ZBVA2>)+:%F47
MVCV9PYMY0,Q[^6#*<\UV?4,%AU&GBZ[A5M>T6K*YQK&8RJY3PL.:FFU>2Z'I
MOP'_`&H8_B7XEU;X7_$'PAJ7PO\`B]X?@^UWGA/5N8M3T\D#^T=&N,`7$`!'
MR@L0"#FN7$9>Z4/;TFJE#H[Z]T_1]>QT4<P4IJA53A5\E8^7O''CSXB_#[]N
M7XCZE\-?AEJ'Q0U6^^#WARQU#2=.N([673;`:S;W":C(TIPZ-/&D&T=Y`:]&
MC0P\\MI2Q57V4%+W;-)MZZ?=J>?6KUJ>82C0I\TM>G3_`(<^R_@A\4/B[X_N
M];A^)?P8U;X6VVG6T,VFW&H7,5RNIRN[K)#&(SPR(`>V=U>5B:&$I-+"UO:7
M?4]7"U\5.+>)I^RM?HUL>*:Q^U?\7?$^N:OH_P`$?V<_%WB6PT34[O2;OQ/X
MH']A:5-=64S03"WBDPY0NK%6!8,N&!YKJHY?A814\5B/9\VRBU<PJXZNY.GA
MZ-[=6A/#7[8OBKPQXMT/P9^T?\)-7^$TGB>]BTW0O%B/]N\*W.HSR+';6EQ>
M+D6WF2,JB1F`RP&*=3*:-:A.O@JW-[-[-J]EKTZ_F94\TJT*T:6+I<JEI=*U
MK['V;XT\:^&/A[X8U7QEXNU6VT?PYHMJUY?:A/(`BQH,HD(!S/-(2%C1>6+`
M=Z\JE0G6<:4(_O.J_._8]2M7A0A[637L^G_`/A6U_:H_:-^);2:Y\#?V=+G4
M/`>]QIFO^-;YM%FUR&)RIN].M2581OCY589Y!R:]?^SLOPZMBL2XU4KI1MU^
M\\IX_'5K?4Z"M?>2:^[U.HT?]M`Z=I7B[1_BI\/-9^&7Q1\+^'-1\0V/A?7"
M(M+\7PZ=`TLB^']5(\N:7C/DY+E<MVQ2_LB-:M1^KU/:4IVUNKH?]JRI4JD:
M]/EK1NGIH?2O@+XK:3XG^#OAWXP:Z;?PQH^K>%(?%6I?:YU$&DVC0&>82S-@
M$(H(XY)(`ZUYV(P<Z>+GA8ZSC+E7:WF>E0Q=.>%A7;M!1N^FOE^A\EP?M6?'
M7XJ3W6I_L[?`=_$/@2TFEAL_%OC2];0+;Q"D+%3/HT+89XFP"N[.58'/->F\
MLPF$C!8JOR3DKM1:_K_,\I9CBL1*7U6C>,'HY(]-^#'[4K>,_&$_PD^*O@O4
MOA1\7;:#[9:Z#JIW:7XDLU7<UWH-_P`+.57GR<LV.?:N;&96J4%B,//VF'>J
M:=VODOQ.G"9GSS]C7A[.LG9JUK^1]A1]>.F#TX'7_/YUY*<N9Q?3_@'KM+1H
MEJB0H`*`/$_VEO\`DW'X_P#_`&1/XJ_^H)KU=V67_M++[;_6:%O_``;`XLR_
MY%V/_P"P>O\`^FI'Y,?\$@A_Q4WQN_[`7A#VZ7^K=/QKZ3BR#4L.[ZR<OR/F
M>%7_`!U;9?JC]RJ^-4%=/FU1]ES+D:Y7H?B]_P`%@A_Q)_@GCC_B9^+3QZ_V
M=;?XU]EPHH\V*_NK3[CY3B9\L,/I;_\`;C_F;_QIX_X)>^!,9_Y`'A,'Z'5)
MN#[5CE__`"/<2O.7YH6.<5DV'LM+&K_P2\\">"_$WP,\07?B+PKH.MW<?C2]
M@6YU33+6\G2'R$VQ+)-&Q$8/11Q5<2UZM'$T8PJ."Y9:+3JBN':%&KAZCE24
MK-:_?Z'PG^TWXBT+XG_MM7'AOQEJT/A[X:>$O%&B^#=Y_=66C>%M#AMI=5C@
MB3Y86GE^UQ@J`!O0=%%>SEM.5/)O:03G7E%M/NW=_KN>/F,XRS14I/DH0EI'
MLC]=(?CY^P];^$E\"1>)/`(\++8?V9_9ALH#"]MY7D[RWD[FE*<^8?F+'.<U
M\K'"9Q5K2K*,^>+OU2]$NW0^EEBLIHT8TO=Y&K-:7MWWWZ]C\C_V=_%&@?"7
M]NNPL?AUK2ZI\/\`7?&5YX9L;JV?%OJ&@:[$9-/0\X8VMU-;QC//[IO6OJL?
M1EB,I?UF#]M2IWO;9J/^9\W@:L<-FB^K/]U4>BZ:L_4_XZ0?\*3_`&K/@Y\<
MK4>1X<^):R_"/X@,@V0K<3KY_A_4;LK@864;%+?QCWKY3!R6*P-;"2_B4[2I
M^45K^=_D?3XQ/"8RAB8Z4Y7C+_$]/R=_7T/O+6]9L/#VAZMX@U&9(-,T73+[
M5[Z=F`6.ST^UEO)Y.3T\J$D>M>/3IR=14TK)M))+5:Z_=J>M4FH4_:7LU&]]
MNET?$O[$6BW6O:/\2OVAO$D?E:W\:?%E_JED]QA38^"])FDM]%MED?[ML\2^
M<PSMR<UZ^:U+?5L%17NT;.RWYI*VGX_>>5E<+_6,74]V52\4WM9.YVWC#]M;
MX!^"-6N_#<.LZEXCU/3)#!>6G@S1+O6H;20$;XY)]/A>*-@3R,UA'*L552J2
MDJ4>TGK\S9YCAZ+]G&'/+O%:'R/^U?\`M2?`3XP?!37=)L+W6-*\=:#?:5XA
M\&IKN@7^D7\6MZ=?021BPN;N!-K21AT8(WS`XKU<NR^MA:SDZL94I0E=1;WM
MIIMW/-S#&T\1148T94ZD9QU?KM?S-W]J3PXGQ;U3]A[0-89Q#XN\1:5+JJH2
M#-;QZ);:K?P$CDI<1VLL+]F65@>M+`R^KT<UE3T<+6#&P]K5RZ,EHS]2K*PL
M]+M+;3=.MH;*QL+>*UL[.W18H+>W@54ABBC3`55C50!CBOF9SE.;E*3<WJV^
M[/HZ<(48\L8J,%T/@C]K+38/#'QO_94^)NE1I;:\WQ&_X0S4)XAY<FHZ'J]J
MZO:7+K@RQH[[P&S@CBO<RR2J83%T*J^",I)=M'^NIXF8Q]CBL-4I*W.XI_-F
MGX(X_P""@_Q@_P"R#>&\'IC_`(J:Q_2N>NDLLPUNLKOULS:CIF=6ZL];>C/N
MS=ZG`Z\G"^K')X&.>?2O)B[<G*[\QZ\OM)KEML]D?*GCG]LCX#?#O6+KPR^M
MW6O:W92NE[IG@W2;G6WM)@V)5N6TZ)UCD#`[MQZ]:]*GEV(JZSE[!=.<\VKC
M\/1_AP]HUOR_B?*W[2W[5?[/'QC^!GC_`,(7-SKFD>(_['DU/PLGB+PWJ.EW
M$>OZ=+%<6$EC<W5NHCN=ZD`!@2"?05Z&"P&(PN(@U4C*F_=FDWL_+NGW.+&X
MJEB,.X^R=.:]Z+=NG3TM?YV*7Q"U:_\`C./V&/A#KUQ)_8/CC2K+QOXTAW$'
M68?"^F01V]C=<_O8G999'5L@L%)Z5M3IQPDLTKTDN:E+EBGV:N[>K9A*HL4L
MNPM1NTXMOI9INWX)'ZM65E::79VVGZ?;0V5C8PQVMI:6\:PP000*(XXHXT`"
MH%`P,5\W*3E*4I/WI.[N?21A[.,8QC\*5K>A\F?MM_"?0OB;\`O&TUY`D'B#
MPCH]YXC\.:Q$HCO;&[L(7EDA6X7#_99X1)')'G!#],UZF2XJ6'QU.*=X3:37
M37JNQYN;86-3!U))<LHIOL?&'Q&U\7G[*_[&OP@O-8C\/Z)\59_"6F^+=4FG
M%M!%X;TB".^U&"68L`D,P7RWW'!#BO7H87GS',:]E)0<N5=>9QYE;\#QZ]?D
MP&!HQ?*WRW>RM>SO^)^DFA_%/X%>&=(T[0-"\=>"=+TC2+2WL;"QM=6L(H;>
MVM8EBB15649PJ#+'DG)/-?/U<#F%9RG.C.[_``\EY'O4L9@:"C3A.*26^BZ;
MOS9\5_MR^,_AI>^$?!?Q:\$>-_#5Q\0_A9XX\/:GI,VEZE:RZE<Z3=ZA#;ZK
MI[B&3S);5K=I&*G*C=DUZN587&T_:4:M*2H.+OS;7ZVZIM?+0\W,L1A&Z=6E
M4C[:+Z?K8_2K0=2CUG2-)UB%=L.K:58:G"O'RQWUK#=(,]SLF4$^U?.U8J%>
M<%>T>9)ORE8]VA)RH4Y-J[2>GFKFS4F@4`%`'B7[2W_)N/Q__P"R)_%7_P!0
M37J[<MTS'`6Z8FA_Z=B<69?\B['_`/8/7_\`34C\A/\`@DOKNB:%XC^-+ZUK
M&EZ.DVB>$EA;4[^UL%F9+_5"PA:ZE02E0ZY"YQN&>M?4\44:U7ZNX4Y-7?PI
MNUUY>A\KPU5IT'6YYJ-XZ7T^U$_;'_A8'@+_`*';PGQ_U,.D_P#R77Q_U'$*
MW[FHK?W'_D?7+'X17C[17/R"_P""NE]9:CX=^!M[IUW;7UG/J/BQH+NSFBN+
M:9?[/MANBGA9D<9'52>:^NX3A[*MBHR3BU&UGIT9\UQ+4A5I8>4'?7IVYXG4
M_&G_`)1>^!!W_L'PD..F3JD^,^E88%*/$&([<S_-%8MP_L*A_=B>@?\`!*#C
MX!>)#Z>.KWI_UQ3I67%-GC:6EK1?Z&_#-XX2K;^9:?(_-+]I_P`#^'_!'[;O
MB*P^)MC>-\/O$WC/3-=OY+9S;33^&M?CMQ>WMO.58`VUPUT3@'_CW/'(KZ+*
MJ\GD\502=2,'96V=K:KU/`S*@HYH_:OEBY:O;3R?F?JAI'_!-_\`8[UW2;37
M=%MM;U#1KZWCO;;4;3Q3!+9R6TL8E5_.6U*J-C`D$@KR"!BOE99YFE*I*DTH
M33::4.J['TD,FP$X1G&JW%I6?-^>NYG?"3]D_P#8D'Q0FC^&^K7VJ>.OA9K&
MGZI-91^)X[J*UU"V=;BW<1I;`7L,<JXD\MB`Q()JL5F&;?5FZRM2K)K:SU6S
M[!AL!E_UE*E*\Z3OTZ/U/K#]J+X9?\+8^"7C/PS;(?[:M;,>(_#4Z`":U\0Z
M"W]HZ;+"PY5_.AVC!YW8KS,MKO#XFG*2LI7@_P#M[1/[ST<QHJOAYP6\+37_
M`&[T/COXB_&[5/BQ^RC\)/".@3R1^/?COJFD?"_6(8CB^TV33+Q;'QK-+&IW
M1A(+*:1L@9BG.?O5ZM+!JAC:U>4>6A0]]/I[RU^:_4\N>+G5PE*BOXM?W7W7
M*T>V_M627/P4_9!UO0O`DCZ-'H^B^'O!=I=V>8Y+#3KN>VTN\O$9?]4PB>1R
M_JQ.:XLO?M\P]JUS.\I)/U27W([,?;"X!4HOET2;7X_B>O\`P(^#OPX^&_PT
M\(Z9X7\/:.ZSZ%IU]?:R]G;W=_K5]?6L5W=ZA=WLJN]Q)/-*SYW8^;`X%98W
M%8F6(K1<Y1A!R2@FU:S\K>IK@<-AEAZ,U!.4DKR/%_V\K3X?Z#^S;X_U'6-%
M\/0:I>V]EI/A^[?3["*^76+Z\A2U%A-Y0D2=1O;*$X`)/`KJR6=>>*C&4Y<D
M83<DVVMM-_,Y\XC1IX9N,$IN<;.UMGKL>;?$'(\<_P#!/,<C&K6XX&.G@B7[
MW/!]O<UTTE^XSA=D<M9_OLM\F?I6>">@YXQQP2<Y/K7S-K2<OY4?2::1Z6/@
M[]M/_D9/V6N#@?'/1N.F!Y'!(].OK7M94KPQ;2_Y=R_)GCYE[M2@GTG%+Y,/
M!.!_P4'^+P/REO@+X;V@\$X\36/W1U(]Q1B%_P`).&:Z2U^YDTG;-*JEI>]N
MA[3^UCXNUOP)^SG\6_$_AR5[76M.\*7BV-W&/FLVO98;"2Z3'W7C@N)"K<;2
M0>U<F6T:<L;AXR5X1=[/TO\`F=>8U9PP==QTG:WWNS^]:?,P/V5_@[\._`7P
M;\#7.AZ-IFHZEX@\.Z;KNN^);RWM[[4]:U+5+9+N[N+F_F1Y'/G2,N`<96M<
M=B:TZ]2+J-1I2:C%:62]#/`X:E3I4TJ=Y3BI2EZ_Y%#]L:Q^'VA_LZ?%77-?
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MWGN7A=&C@2<AV<,N`I)->A0JRCC\SHTY<D^:3@_165D<56E36!P%:<>:/+%2
MCVUNS[[M/V-?V4KVVMKVR^$/A2YL[N&.YM+F&?4WAGMYT66*:*0:B0T;HRL"
M.S5X<\US*E)1]K)3BVFK)6?W'L0R[`SCS*FO9R5T[].XRZ_8X_9,T](I;_X2
M>#;.*2XABA>]NKV")[EV_<0J;C4@CS/(,*G))'`JO[5S%I_[1*R6JLO\@>79
M?%P2H13EHCZETZRM=-M+33K&!;:RL+2"RM+=`0D%M:11P001Y)/EQQ1H@SV4
M5Y<I.4G)[N^OJ[_B>E&"IQ4(KE4;)>B6A?I#"@`H`\X^,7A74?'7PC^*?@C1
MWACU;QC\./&_A72WN"5MTU'Q#X9U/2+)YV'*PK<WD18CHH-=.#JJAB\+7E\-
M&M2F_2$XR?Y'/BZ3K83$T8_%5I5(+UE!Q7YGX)C_`()8?M%IG9K'A&/_`'+Z
M=#[`%7'X?4U]U7XDP%6,4XK3?0^*I</XVF_=O'YCC_P2R_:-P1_;GA;/_80N
M?_CE1+/<LLDHK[BO[!Q_/?F=O4^IOC+^PK\8/'O[/_[/?PST>_\`#R>(/A?%
MXA3Q#-=W,HM)FU6-$MOL<F[=)M*G)).,UY6%S3"X?&XFJI<M.HERZ>5F>EB,
MJQ%7"4:5N:<'KK;JG^A]$?$3]F;Q[XH_8N\-?`'3KO2D\9Z3IFAV5U<S2L--
M,NG7DEQ/Y<H.<%'`4YZUPX?'4J>9U,5)VIR;:^=CLKY=4EEU/#17OP6J.J_8
M=^`'C/\`9U^%VK^#_&]QIESJE[XEN=6A?2I&E@%O-$J*&+$[9,CD"HSS'T\=
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MLIGA'[2M4?M+[7/T9Q\N"`5^Z5(RI!R&SZJ03D'M7SUY6[.Z:Z6/?Y(7\K'P
M+\+OV1-4\"_M->+/B?>:G;7/PX@N]6USX<^&P[,VA:]XIBMO^$@N1;D[(/WL
M<HC*@?(]>[7S*,\!"C%_O9*U3^O-'B4,!4AC:E22M1B[P_X"/LGXA>!-`^)?
M@SQ%X%\3VPN=#\2:=/IU\@X95F0[9XB?NRQ2;67W6O'P]66'JQJQ=I1=[?H>
MKB*,:]*5)K22MZ>9\(>'?`7[;OP*L8_`OP_U#P5\4_`FF9MO"]YXHNGT_7-*
MTT$_9[.\D+#[3'`I"KCHH`%>Y*ME>*2JUFZ=5_$DK'C0H9AA&Z5&*G26UW^A
ME>._V3/CG\>?"?B+5/C?XVT>]\8#37A^'G@S2!-;^#?"VISRH9=5O=K!M0OQ
M`&C21MP7/'%51Q^"P=3DP\?W3B^:5K.]M/4FM@,7B8<U72I&2M&^EKZGOOBG
MX#>*]:\2?LKZO:W^FI;_``2OH;GQ,DAD$EZB>'9-(8:=SM)\]@WS9RM<5/&4
MXTL?%NSQ"7+_`,$[*N#FZF"E%:4'[Q]=_08R<X[`C.#7DK?71'J-?RGS1^T'
M\'?$7Q4U?X,7^@WEA:1?#KXDV'C'5UO=^ZYT^VCV206NPX$Y.",\5Z.`Q%/#
M>WC/13IRBO5IV_,X,=AYXA4'%>]3G%OT3U.$^/WP*^)M]\2_#WQZ^`>NZ5H_
MQ(T?1I?#.N:3KBO_`&/XI\/-(98K6Z:/&R6*0Y5CT.".0,;8'$X=49X;%?PW
MJNJ77Y=T8X["UW6AB,*OWD=^G]7.H^&_ACX[^/-$\<:)^TO9^#%\.>)=%?0[
M/PWX;#W!6*Z21+VXO+B3*N^&1H@.59`3R*C$3PF'E2E@9-RIRYKM?AZ-%T*>
M*K1J0QD%&,U:R>W].S/`?#GPK_;&_9WMV\&?"/5_"GQ0^&EM-(OAFR\77+6.
MN>'[)Y&>*R-TQ"S6T:L``#QCCK7=.ME>-C&==O#54M>5;^IQTZ.98*4HT(^V
MIMZ<SV7H-\6_LQ?'SX_>'/$5W\>_%^B1Z@NBWT7@3X?>'3-'X6TOQ!<1+'::
MOKLP8-J,L'SE5R0I8D4H8[!8.5..%CI]J=K.W7U8IX+%8MR>*]U+:*VO^A]B
M?#WPUIWPZ^#W@/X>^/[[07-AX?TWPCJ`U"2!-+U:^,)@:S@2].)C.-P6,Y)S
MTXKR:M:53&U:V'<D^:Z:T:T_J_<]6G3AA\+3HU;<J5K/;=O]3YSUW_@G_P##
M&;6;[5O`GC'X@_"ZUU:4SWVC>"O$5YIVD2M*Q:4Q6\4RB,,22%&5&>!BNZCF
MTXZ5L/&M*/\`,NOHU_78X:N5QDDZ->5&,G]G3?T_X!R?QE^%'PA_98_9R^)L
MWAZTEN_&GCS1W\(6FNZ[<MJ?BWQ/K&N.MI:V$5S.6F=-SF9XHOEQ$6;.!6^#
MQ.(Q>.A.WLZ5'WG&.D4MO\_N,<7A</@L)*FY<]6IHF]W_E_7F?3'P_\`A'H^
MI_LU^#/A%X[TR*^TZ?X>Z3H>M6,R@>7(]@A>2,D9AN896#(PP59*X,3BI0S*
MM6I:6F_+39Q?J=^'PL98"C2J+['W/NCYDT3X8_ME_`&%O"?PJU[PO\5OAY:E
MHO#EGXRN6LM=T&R#'R;.2\=L7$4:D*O)P``.!7HNME>+<:N(;I5;>\DK:^O4
MXEA\?A5.E07/3O[MV=!H'[/?QT^+OC#P_P",OVF_&&GVV@^%=2MM8T'X8^"9
MKBWTHZI:.'M;S6+U'!NFCD4,`#UZ=37/6Q>#P]*=#"4U4YU\<EKJ52PF+K5J
M=;$R=+D?PQ?];GUYH$'CY/B!XCFUB>W;P6]@%T*!"GVB*]$]H<RA><&$7/7V
MKSZDJ/L(*"M435_2SO\`C8].G&K&K+F=Z=G;UNK?A<],KE.@*`"@!#T-`#-I
M]?U/^%`!M/K^I_PH`38WM],D`?3B@`V'U`[8''].M`!Y9]?IV_/B@`V$>F,Y
M'4$?I0`NUO7]3_+%`">6?4?RH`/+/J/S/^%`!L/J./K_`(4`'EGU`_S]*`#8
MPZ'\,D<_E0`;#V/US_2@`\L^H_7_``H`-A]OU_PH`-C=B!^?\L4``0^P(Z$9
M'YC%`!L;_9!]03_+%`!L8="/IT_D.*``(P],^Y/^'6I2Y7=%-Z)=CQ_XV?!'
MPK\=/"`\(^+)+^VAM;Z+5M)U/2KR6RU#2M7MT=+:_MI(BO[V,2/@$XYKOP6,
ME@ZCFH1DI:.+73UZ/\SCQ>%AB8*/,X\OG;\CY2L_@5^VSX`C&C?#SX^>"?%/
MARW`CL#\2H-9M]7M+?HL33:5X=U%;AD7@.T@)QDXKTWCLHJOGQ&&J\_7DA3M
M_P"G$>;+!9E3M##5Z2IK;GE-/\*;1T?@G]DOQIKOCC1OB1^TG\2$^)VM^&9A
M>>&/"NEQSP>#-#OP05O%@N;6V>^F4_=:6W0K@8K"MF%"E"4,NA.DI:/G44_E
MRRD:T<!6FU+'2A-QVY')_P#I48GW2(R`%&U0HP`.`/8#'`KQWO?J]SUHQ45R
MQ5HK878P]/P)!'TXI#%V'U_/D_RH`55*]_\`/&.U`#Z`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
